TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15531006
Drug: Hydrochlorothiazide 12.5
Normalized name: hydrochlorothiazide 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 12.5 mg added (level 3)
Study: 15531006
Drug: Combined treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatments (Valsartan and Amlodipine)
Study: 8356997
Drug: nabumetone (1,000‐2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: nabumetone (1,000‐2,000 mg/day)
Study: 8356997
Drug: diclofenac (100‐200
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac (100‐200 mg/day)
Study: 8356997
Drug: naproxen (500‐1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen (500‐1,500 mg/day)
Study: 28851317
Drug: NaturaLyte® acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaturaLyte® acid concentrate (4 mEq/L acetate)
Study: 28851317
Drug: GranuFlo® acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: GranuFlo® acid concentrate (8 mEq/L acetate)
Study: 25498218
Drug: Immediate chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate chemotherapy (four cycles of gemcitabine plus cisplatin, high-dose methotrexate, vinblastine, doxorubicin, and cisplatin [high-dose MVAC])
Study: 25498218
Drug: Deferred chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred chemotherapy (six cycles at relapse)
Study: 25498218
Drug: Deferred chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred chemotherapy
Study: 23683266
Drug: 3.6 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 g/d of omega-3 fatty acid (O3A) ethyl esters
Study: 12839147
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V 500 mg 3 times daily for 10 days
Study: 7848019
Drug: Twice-daily, low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily, low-molecular-weight heparin
Study: 2248843
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bupivacaine and lignocaine
Study: 30422193
Drug: Sedative-hypnotics (intervention)
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedative-hypnotics (intervention)
Study: 30422193
Drug: Sedative-hypnotics (control)
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedative-hypnotics (control)
Study: 30422193
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drugs (intervention)
Study: 30422193
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drugs (control)
Study: 27375714
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg propofol
Study: 27375714
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg propofol plus 0.5 mg/kg ketamine
Study: 26242117
Drug: Celecoxib Capsule
Normalized name: Celecoxib Capsules
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib Capsule (Control)
Study: 15657341
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and radiation therapy (37.5 Gy in 16 fractions)
Study: 10589645
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (warm blankets and/or radiant heat)
Study: 7847521
Drug: Ceftriaxone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (1 gm daily intravenous)
Study: 7847521
Drug: Cefazolin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (2 gm three times daily intravenous)
Study: 1819436
Drug: Combined yellow‐fever‐measles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined yellow‐fever‐measles vaccine
Study: 1819436
Drug: Yellow‐fever and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellow‐fever and measles separate administration
Study: 31877392
Drug: Infant carrying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant carrying (babywearing) for 1 hour daily for 3 months
Study: 28466151
Drug: Delay in
Normalized name: Delayed Release Oral Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delay in antimicrobial therapy.
Study: 26503395
Drug: Supportive educational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive educational intervention for carers (4 components: initial telephone assessment, tailored resource folder, home visit, ongoing monthly support for 12 months)
Study: 23813851
Drug: Nurse-coordinated prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-coordinated prevention programme (four outpatient nurse clinic visits focusing on healthy lifestyles, biometric risk factors, and medication adherence)
Study: 22118755
Drug: Longevinex administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longevinex administered for 3 months (Group A)
Study: 22118755
Drug: Longevinex administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longevinex administered between 3 and 6 months (Group B)
Study: 19302901
Drug: Posaconazole 200
Normalized name: posaconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole 200 mg BID for 7 days
Study: 19302901
Drug: Posaconazole 400
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole 400 mg BID for 7 days
Study: 19302901
Drug: Ketoconazole 400
Normalized name: ketoconazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 400 mg once daily for 7 days
Study: 19302901
Drug: Midazolam (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (oral 2 mg and IV 0.4 mg) administered with either azole
Study: 17582178
Drug: Systemic steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic steroids (Methyl prednisolone 0.5 mg/kg/day in two divided doses)
Study: 17582178
Drug: Nebulized steroids
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized steroids (Budecort 50 mcg/dose twice daily)
Study: 15449752
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml of 6% hydroxyethylstarch (HES)
Study: 15449752
Drug: 1000 ml
Normalized name: TPN Bag 1000 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 ml of 6% hydroxyethylstarch (HES)
Study: 11343734
Drug: Treatment by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment by primary-care physician
Study: 11343734
Drug: Treatment by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment by pain specialist
Study: 11343734
Drug: Overall desire
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall desire for additional treatment
Study: 9518909
Drug: temazepam 10
Normalized name: temazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: temazepam 10 mg
Study: 7853442
Drug: Manioc Salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manioc Salt Solution (MSS)
Study: 7853442
Drug: Pap Salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pap Salt Solution (PSS)
Study: 7853442
Drug: World Health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: World Health Organization/Oral Rehydration Solution (WHO/ORS)
Study: 189333
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg ACTH 4-10 subcutaneously
Study: 31693803
Drug: Tetravalent dengue
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent dengue vaccine (TAK-003)
Study: 28481726
Drug: RV3-BB vaccine
Normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RV3-BB vaccine (both schedules)
Study: 28481726
Drug: RV3-BB vaccine
Normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RV3-BB vaccine
Study: 25954737
Drug: Azithromycin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (30 mg/kg, three once-weekly doses)
Study: 19114797
Drug: Documented ventricular
Normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Documented ventricular tachycardia (VT) at the time of ICD implant
Study: 1565758
Drug: placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets (usual sodium)
Study: 29882841
Drug: 2000 IU
Normalized name: D 2000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 IU vitamin D₃ daily
Study: 29882841
Drug: 50,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50,000 IU vitamin D₃ monthly
Study: 27640797
Drug: Drospirenone and
Normalized name: drospirenone and estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone and ethinylestradiol tablets group
Study: 22684569
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with tyrosine, lecithin, L‐glutamine and 5‐HTP, n=41
Study: 20170333
Drug: Fixed-dose budesonide/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose budesonide/formoterol 160/4.5 microg x 2 inhalations (320/9 mug) twice daily
Study: 20170333
Drug: Fixed-dose fluticasone
Normalized name: fluticasone Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose fluticasone propionate/salmeterol 250/50 microg twice daily
Study: 20170333
Drug: Adjustable-dose budesonide/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjustable-dose budesonide/formoterol (adjustable from 320/9 microg twice daily to 320/9 microg once daily or 640/18 microg twice daily)
Study: 18693154
Drug: BPO 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPO 10% gel
Study: 7881965
Drug: Initial cytotoxic
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial cytotoxic or endocrine treatment followed by mastectomy
Study: 7881965
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Immediate modified radical mastectomy and Initial cytotoxic or endocrine treatment)
Study: 29474935
Drug: Turbuhaler® M3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turbuhaler® M3 (1.5 mg terbutaline)
Study: 29474935
Drug: Turbuhaler® M2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turbuhaler® M2 (1.5 mg terbutaline)
Study: 29474935
Drug: Turbuhaler® M3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turbuhaler® M3 (0.5 mg terbutaline)
Study: 29474935
Drug: Turbuhaler® M2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turbuhaler® M2 (0.5 mg terbutaline)
Study: 16330394
Drug: Ethanol (0.97+/‐0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.97+/‐0.12 g/kg body weight)
Study: 2716162
Drug: Sustained-release PPA
Normalized name: phenylpropanolamine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release PPA hydrochloride 75 mg once per day
Study: 2716162
Drug: Immediate-release PPA
Normalized name: phenylpropanolamine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release PPA hydrochloride 25 mg three times per day
Study: 2716162
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules three times per day
Study: 28182127
Drug: Metoprolol (23.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (23.75 or 47.5 mg, qd PO, dose escalated with 23.75 mg each time until target heart rate [HR] <70 bpm was achieved)
Study: 26556275
Drug: Clindamycin, ciprofloxacin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin, ciprofloxacin, amoxicillin, and minocycline
Study: 23799683
Drug: Self-administered web-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered web-based computer intervention
Study: 21326107
Drug: Olprinone at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olprinone at 0.2 μg·kg(‐1)·min(‐1)
Study: 21326107
Drug: Olprinone at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olprinone at 0.4 μg·kg(‐1)·min(‐1)
Study: 21326107
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0 μg·kg(‐1)·min(‐1))
Study: 19057445
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone 5 mg/kg/day in four divided doses for 7 days
Study: 17721240
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of propofol (2.5 mg/kg)
Study: 17721240
Drug: 1-, 2-,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-, 2-, or 3-min infusion of propofol (2.5 mg/kg)
Study: 11027910
Drug: Gabapentin (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (titrated from 1,200 mg/day to a maximum of 2,400 mg/day)
Study: 11027910
Drug: Amitriptyline (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (titrated from 30 mg/day to a maximum of 90 mg/day)
Study: 8450987
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment with antiepileptic drugs (carbamazepine, phenytoin, phenobarbital, or sodium valproate)
Study: 8450987
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment with the same antiepileptic drugs
Study: 6115730
Drug: Propranolol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (all doses)
Study: 28141545
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (1000 mg containing 180 mg EPA and 120 mg DHA)
Study: 23103775
Drug: Propofol 1
Normalized name: propofol 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1 mg kg(‐1) (Group P)
Study: 23103775
Drug: Fentanyl 1
Normalized name: fentanyl 1.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1 µg kg(‐1) (Group F)
Study: 17457713
Drug: 3-in-1 femoral
Normalized name: SUS SCROFA TEMPORAL LOBE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-in-1 femoral nerve block with 40 ml of ropivacaine 0.375% (Group R)
Study: 17457713
Drug: Morphine loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine loading dose of 2 mg (Group S)
Study: 12637461
Drug: Tamoxifen plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen plus aminoglutethimide (500 mg/d for the first 2 years)
Study: 12637461
Drug: Tamoxifen (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (40 mg/d for the first 2 years, then 20 mg/d for 3 years)
Study: 10925565
Drug: 5 x
Normalized name: PAD,ABDOMINAL 5 X 9 STERILE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 x 10(‐4)% fentanyl (10‐20 mL) administered epidurally during early first-stage labor (Group A)
Study: 10925565
Drug: No analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: No analgesic during the early first stage of labor (Group B)
Study: 10925565
Drug: No analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: No analgesic during the entire labor course (Group C)
Study: 6143538
Drug: Betaxolol 20
Normalized name: betaxolol 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 20 mg
Study: 30786187
Drug: Plazomicin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plazomicin (15 mg per kilogram of body weight once daily)
Study: 27504543
Drug: 20% trichloro‐acetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% trichloro‐acetic acid peel plus 5% topical magnesium ascorbyl phosphate
Study: 19427744
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (cisplatin 50 mg/m², Days 1 and 8; paclitaxel 175 mg/m² Day 1, every 21 days) followed by concurrent CRT (accelerated-hyperfractionated regimen, 45 Gy, 2 x 1.5 Gy/d, cisplatin 50 mg/m², Days 64 and 71, vinorelbine 20 mg/m², Days 64 and 71)
Study: 19427744
Drug: Definitive radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Definitive radiotherapy (total dose 65 or 71 Gy, depending on the mean lung dose) with additional concurrent chemotherapy (cisplatin 40 mg/m², Day 85; vinorelbine 15 mg/m², Days 85 and 92)
Study: 17513184
Drug: Antenatal magnesium
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal magnesium sulphate therapy
Study: 17513184
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antenatal magnesium sulphate therapy)
Study: 7786657
Drug: Felodipine 2.5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 2.5-10 mg twice daily
Study: 6504944
Drug: Pentoxifylline ('Trental'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline ('Trental' 400) 400 mg (2 tablets)
Study: 30451531
Drug: Light force
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light force (300 g) CHG
Study: 30451531
Drug: Heavy force
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavy force (500 g) CHG
Study: 16493167
Drug: Continuous femoral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous femoral nerve block with ropivacaine and oral hydrocodone
Study: 16493167
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of bupivacaine/morphine and oral oxycodone
Study: 9072885
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron supplementation (Actiferrin, 3 x 1 cps/d, 724.5 mg elemental Fe per week)
Study: 9072885
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron supplementation (Ferrum-Lek, 1 vial per week, 100 mg elemental iron per week)
Study: 1306677
Drug: Oral-B 35
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral-B 35 manual toothbrush
Study: 3866334
Drug: Xylocaine 5%
Normalized name: Xylocaine 5% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylocaine 5% ointment
Study: 25022705
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of IPL-F and LF-QS-Nd:YAG laser
Study: 21438412
Drug: Naoxinduotai capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naoxinduotai capsule + perindopril
Study: 12107665
Drug: Risedronate 5
Normalized name: risedronate 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 5 mg daily (stratified by age 64 years)
Study: 12107665
Drug: Risedronate 5
Normalized name: risedronate 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 5 mg daily (stratified by age 76 years)
Study: 10023618
Drug: Network Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Network Therapy (NT)
Study: 7581086
Drug: FK506 (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK506 (0.05 mg/kg i.v. or 0.15 mg/kg orally twice a day)
Study: 1698845
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 1 mg/kg methylprednisolone
Study: 417377
Drug: Intramuscular loxapine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular loxapine
Study: 417377
Drug: Oral loxapine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral loxapine
Study: 31743569
Drug: Ipragliflozin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipragliflozin (50 mg, once daily)
Study: 31743569
Drug: Placebo (initially)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (initially) then switched to Ipragliflozin (50 mg, once daily)
Study: 22770818
Drug: Single sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single sterile water injection (n=147)
Study: 22770818
Drug: Four sterile
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four sterile water injections (n=158)
Study: 20396720
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of artrofoon and anaferon
Study: 15114907
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of two types of judgment with two stimulus dimensions
Study: 11557191
Drug: Pyridoxine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxine (100 mg/day)
Study: 8269914
Drug: Folate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folate (5 mg/day)
Study: 9590462
Drug: Irbesartan 300
Normalized name: irbesartan 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 300 mg taken orally once daily for 7 consecutive days
Study: 9590462
Drug: Irbesartan administration
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irbesartan administration on day 1
Study: 9590462
Drug: Irbesartan administration
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irbesartan administration on day 7
Study: 7599468
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of i.v. antibiotics tobramycin
Study: 7599468
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of i.v. antibiotics Timentin
Study: 7599468
Drug: Flushing solution
Normalized name: WATER 985.77 g in 1000 mL TOPICAL SOLUTION [Eyewash Flushing Solution]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flushing solution (both normal saline and heparinised saline)
Study: 3279997
Drug: No maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: No maintenance treatment (stopping MP)
Study: 27999851
Drug: Placebo (Lecithin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Lecithin, 2400 mg daily)
Study: 27999851
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (eicosapentaenoic acid (EPA); 1770 mg, and docosahexaenoic acid (DHA); 390 mg, daily)
Study: 27999851
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (1,000 IU daily)
Study: 23791619
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg MK-7123
Study: 16169314
Drug: Clopidogrel in
Normalized name: Product containing clopidogrel in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel in addition to low- to moderate-dose aspirin